Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 May;103(1):1263–1267. doi: 10.1111/j.1476-5381.1991.tb12334.x

Specific neurokinin receptors mediate plasma extravasation in the rat knee joint.

F Y Lam 1, W R Ferrell 1
PMCID: PMC1908078  PMID: 1715229

Abstract

1 Plasma extravasation in the rat knee joint was induced by intra-articular injection of neurokinins and specific neurokinin receptor agonists. 2 Pronounced plasma extravasation was produced by substance P (SP, 4-185 microM) and to a lesser extent by neurokinin-B (NKB, 83-413 microM), whereas neurokinin-A (NKA, 88-440 microM) and calcitonin gene-related peptide (CGRP, 26-130 microM) had no significant effect. 3 The specific neurokinin1 receptor agonist [Sar9, Met(O2)11]-substance P (NK1 agonist) in doses of 0.4-70 microM appeared to be more potent than SP in eliciting plasma extravasation. The neurokinin2 receptor agonist [Nle10]-neurokinin A4-10 (NK2 agonist) was not effective at 70 microM but produced a small and significant effect at 330 microM, whereas the neurokinin3 receptor agonist [MePhe7]-neurokinin B (NK3 agonist) was without effect at 40 microM or 400 microM. 4 Injections of SP or NKA into the synovial cavity of the rat knee were equally effective in producing marked plasma extravasation in remote sites such as the forelimb and hindlimb paws. 5 Co-administration experiments showed that the effects of SP were synergistic with NKA or the NK1 receptor agonist, but not with CGRP or the NK2 receptor agonist. 6 The rank order of potency was NK1 agonist greater than or equal to SP greater than NKB greater than NK2 agonist suggesting that NK1 receptors mediate plasma extravasation in the rat knee joint.

Full text

PDF
1263

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. V., Helme R. D., Thomas K. L. NK-1 receptor mediation of neurogenic plasma extravasation in rat skin. Br J Pharmacol. 1989 Aug;97(4):1232–1238. doi: 10.1111/j.1476-5381.1989.tb12583.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beaujouan J. C., Torrens Y., Viger A., Glowinski J. A new type of tachykinin binding site in the rat brain characterized by specific binding of a labeled eledoisin derivative. Mol Pharmacol. 1984 Sep;26(2):248–254. [PubMed] [Google Scholar]
  3. Brain S. D., Williams T. J. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol. 1985 Dec;86(4):855–860. doi: 10.1111/j.1476-5381.1985.tb11107.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brain S. D., Williams T. J. Interactions between the tachykinins and calcitonin gene-related peptide lead to the modulation of oedema formation and blood flow in rat skin. Br J Pharmacol. 1989 May;97(1):77–82. doi: 10.1111/j.1476-5381.1989.tb11926.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brain S. D., Williams T. J. Substance P regulates the vasodilator activity of calcitonin gene-related peptide. Nature. 1988 Sep 1;335(6185):73–75. doi: 10.1038/335073a0. [DOI] [PubMed] [Google Scholar]
  6. Buck S. H., Burcher E., Shults C. W., Lovenberg W., O'Donohue T. L. Novel pharmacology of substance K-binding sites: a third type of tachykinin receptor. Science. 1984 Nov 23;226(4677):987–989. doi: 10.1126/science.6095447. [DOI] [PubMed] [Google Scholar]
  7. Drapeau G., D'Orléans-Juste P., Dion S., Rhaleb N. E., Rouissi N. E., Regoli D. Selective agonists for substance P and neurokinin receptors. Neuropeptides. 1987 Jul;10(1):43–54. doi: 10.1016/0143-4179(87)90088-6. [DOI] [PubMed] [Google Scholar]
  8. Foreman J. C., Jordan C. C., Oehme P., Renner H. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol. 1983 Feb;335:449–465. doi: 10.1113/jphysiol.1983.sp014543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gamse R., Holzer P., Lembeck F. Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol. 1980 Feb;68(2):207–213. doi: 10.1111/j.1476-5381.1980.tb10409.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harada M., Takeuchi M., Fukao T., Katagiri K. A simple method for the quantitative extraction of dye extravasated into the skin. J Pharm Pharmacol. 1971 Mar;23(3):218–219. doi: 10.1111/j.2042-7158.1971.tb08647.x. [DOI] [PubMed] [Google Scholar]
  11. Jancsó N., Jancsó-Gábor A., Szolcsányi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother. 1967 Sep;31(1):138–151. doi: 10.1111/j.1476-5381.1967.tb01984.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kangawa K., Minamino N., Fukuda A., Matsuo H. Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem Biophys Res Commun. 1983 Jul 29;114(2):533–540. doi: 10.1016/0006-291x(83)90813-6. [DOI] [PubMed] [Google Scholar]
  13. Lam F. Y., Ferrell W. R. Capsaicin suppresses substance P-induced joint inflammation in the rat. Neurosci Lett. 1989 Oct 23;105(1-2):155–158. doi: 10.1016/0304-3940(89)90028-1. [DOI] [PubMed] [Google Scholar]
  14. Lam F. Y., Ferrell W. R. Inhibition of carrageenan induced inflammation in the rat knee joint by substance P antagonist. Ann Rheum Dis. 1989 Nov;48(11):928–932. doi: 10.1136/ard.48.11.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lam F. Y., Ferrell W. R. Mediators of substance P-induced inflammation in the rat knee joint. Agents Actions. 1990 Nov;31(3-4):298–307. doi: 10.1007/BF01997623. [DOI] [PubMed] [Google Scholar]
  16. Lee C. M., Campbell N. J., Williams B. J., Iversen L. L. Multiple tachykinin binding sites in peripheral tissues and in brain. Eur J Pharmacol. 1986 Nov 4;130(3):209–217. doi: 10.1016/0014-2999(86)90270-0. [DOI] [PubMed] [Google Scholar]
  17. Lembeck F., Donnerer J., Barthó L. Inhibition of neurogenic vasodilation and plasma extravasation by substance P antagonists, somatostatin and [D-Met2, Pro5]enkephalinamide. Eur J Pharmacol. 1982 Nov 19;85(2):171–176. doi: 10.1016/0014-2999(82)90462-9. [DOI] [PubMed] [Google Scholar]
  18. Lembeck F., Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol. 1979 Dec;310(2):175–183. doi: 10.1007/BF00500282. [DOI] [PubMed] [Google Scholar]
  19. Minamino N., Kangawa K., Fukuda A., Matsuo H. Neuromedin L: a novel mammalian tachykinin identified in porcine spinal cord. Neuropeptides. 1984 Mar;4(2):157–166. doi: 10.1016/0143-4179(84)90126-4. [DOI] [PubMed] [Google Scholar]
  20. Ogawa T., Kanazawa I., Kimura S. Regional distribution of substance P, neurokinin alpha and neurokinin beta in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection. Brain Res. 1985 Dec 16;359(1-2):152–157. doi: 10.1016/0006-8993(85)91423-4. [DOI] [PubMed] [Google Scholar]
  21. Regoli D., Drapeau G., Dion S., D'Orléans-Juste P. Pharmacological receptors for substance P and neurokinins. Life Sci. 1987 Jan 12;40(2):109–117. doi: 10.1016/0024-3205(87)90349-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES